Encodes An Animal Polypeptide Patents (Class 536/23.5)
  • Patent number: 10626159
    Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding the same, a T cell expressing the TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing the tumor-associated antigen.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 21, 2020
    Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
  • Patent number: 10537636
    Abstract: The present document describes a method of inhibiting cancer tumor growth in a patient in need thereof, comprising at least a first treatment comprising steps a) and b): a) administering to the patient an immune adjuvant in combination with a therapeutic monoclonal antibody specific for a tumor associated antigen; and b) administering to the patient the immune adjuvant; and a final treatment consisting of administering to the patient the therapeutic monoclonal antibody specific for a tumor associated antigen, wherein time between step a) and step b) is a time sufficient for treatment of the patient with the immune adjuvant, and wherein time between the step b) and the final treatment is from about 10 to about 14 weeks.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: January 21, 2020
    Assignee: Oncoquest Inc.
    Inventors: Christopher F. Nicodemus, Ragupathy Madiyalakan
  • Patent number: 10508139
    Abstract: The use of HspBP1 protein or part thereof for the preparation of an anti-tumor pharmaceutical composition, and its optional combination with one or more chemotherapeutic agents. A gene construct for the expression of said protein; a production process; a process of evaluation of tumor cells; and a method of sensitization of tumors to chemotherapeutic agents. A new experimental model in vivo and in vitro for the development/evaluation of anti-tumor agents. The pharmaceutical compositions provide anti-tumor action and have high specificity to neoplastic cells, resulting in less cytotoxicity to normal dividing cells, in part as a solution to the drawbacks of currently known chemotherapy therapeutic regimens.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: December 17, 2019
    Assignee: União Brasileira de Educação e Assistência, mantenedora da PUCRS
    Inventors: Cristina Beatriz Cazabuena Bonorino, Ana Paula Duarte de Souza
  • Patent number: 10494428
    Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: December 3, 2019
    Assignee: Ann & Robert H. Lurie Children's Hosp. of Chicago
    Inventors: Menotti Ruvo, Annamaria Sandomenico, Antonio Leonardi, Luca Sanguigno, Mary J. C. Hendrix, Elisabeth A. Seftor, Richard E. B. Seftor, Luigi Strizzi, Zhila Khalkhali-Ellis
  • Patent number: 10392447
    Abstract: Provided are novel human-derived dipeptide repeat (DPR) specific antibodies as well as synthetic variants and biotechnological derivatives thereof, preferably capable of binding C9ORF72 DPRs, as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for DPRs and DPR proteins such C9ORF72 DPRs are also disclosed. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: August 27, 2019
    Assignee: Neurimmune Holding AG
    Inventors: Fabio Montrasio, Jan Grimm
  • Patent number: 10357539
    Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of Princeton University, Wisconsin Alumni Research Foundation
    Inventors: Yibin Kang, Yongna Xing, Liling Wan, Feng Guo
  • Patent number: 10357562
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: July 23, 2019
    Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC
    Inventors: Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
  • Patent number: 10266592
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: April 23, 2019
    Assignee: Seattle Children's Hospital
    Inventor: Michael C. Jensen
  • Patent number: 10214579
    Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10F3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: February 26, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Amna Saeed-Kothe, Jonathan Davis, Tracy S. Mitchell
  • Patent number: 10150808
    Abstract: The present inventors successfully provided constant regions capable of enhancing the agonist activity of antibodies through amino acid sequence alterations. Specifically, agonist activity was found to be enhanced in antibodies having a constant region in which amino acids of the antibody heavy chain constant region are substituted or deleted, or antibodies having a constant region in which the hinge region amino acids are substituted. Use of such antibodies as pharmaceutical formulations can provide pharmaceutical formulations with improved performance.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: December 11, 2018
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Taichi Kuramochi, Shigero Tanba, Tomoyuki Igawa, Atsuhiko Maeda, Kiyoaki Sakata, Mika Endoh
  • Patent number: 10124037
    Abstract: The invention provides for methods for treating an inflammatory disease of the digestive system in a subject by administering a trefoil family molecule. The invention provides for methods for treating a digestive system cancer in a subject by administering a trefoil family molecule. The invention provides for methods for cell proliferation in a subject by administering a trefoil family molecule.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 13, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Timothy C. Wang, Jan K. Kitajewski
  • Patent number: 10053492
    Abstract: Protein indicators useful for calcium imaging, in particular, red genetically-encoded calcium indicators (GECIs) disclosed herein rival best-of-class green GECIs in terms of sensitivity for detecting neural activity, and can be monitored in vivo. The presently-disclosed subject matter further includes a method of monitoring cell activity comprising stimulating a cell comprising a red GECI polypeptide; and detecting fluorescence emitted by the cell.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: August 21, 2018
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Douglas S. Kim, Loren L. Looger, Eric R. Schreiter, Karel Svoboda
  • Patent number: 10047346
    Abstract: This document provides methods and materials related to induced pluripotent stem cells. For example, induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells are provided. In addition, methods and materials for using induced pluripotent stem cells to repair tissue (e.g., cardiovascular tissue) in vivo as well as methods and materials for using induced pluripotent stem cells to assess their therapeutic potential in appropriate animal models are provided.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: August 14, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Yasuhiro Ikeda, Andre Terzic, Timothy J. Nelson, Amber A. Mael, Almudena J. Martinez Fernandez, Satsuki Yamada
  • Patent number: 9987336
    Abstract: Methods for attenuating or treating, or reducing the mortality of sepsis or septic shock using an ectonucleotidase such as CD39 or CD73 are provided.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: June 5, 2018
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Gyorgy Hasko, Zoltan Nemeth
  • Patent number: 9963737
    Abstract: The present invention relates to a method for amplifying and detecting a target nucleic acid in a sample, said target nucleic comprising subgroups with sequence variations and/or individual mutations, wherein an amplification of the nucleic acids in said sample is carried out. This amplification involves a polymerase, primers for generating an amplicon and at least two detectable probes specific for different sequence portions of said amplicon. Detection of the obtained amplicon is brought about by detecting hybridization of the probes mentioned above to said different sequence portions of the amplicon. The invention further provides reaction mixtures and kits for amplifying and detecting a target nucleic acid comprising subgroups with sequence variations and/or individual mutations involving the use of at least two detectable probes specific for different sequence portions of an amplicon.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: May 8, 2018
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Bergmann, Dorothea Sizmann, Heike Zitzer
  • Patent number: 9944990
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 17, 2018
    Assignee: GENOMIC HEALTH, INC.
    Inventors: Melody A. Cobleigh, Steven Shak, Joffre B. Baker, Maureen T. Cronin
  • Patent number: 9932379
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 3, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 9840738
    Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: December 12, 2017
    Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
  • Patent number: 9713626
    Abstract: Pharmaceutical compositions comprising an mRNA-loaded nanoparticle, wherein the mRNA is an in vitro transcribed mRNA and has a coding sequence at least 80% identical to SEQ ID NO: 3, and wherein the mRNA encodes a human cystic fibrosis transmembrane conductance regulator (CFTR) protein comprising the amino acid sequence of SEQ ID NO:1 are provided. The present invention is particularly useful for treating cystic fibrosis.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: July 25, 2017
    Assignees: RaNA Therapeutics, Inc., Ethris GmbH
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
  • Patent number: 9694058
    Abstract: The tumor-necrosis factor superfamily member LIGHT (p30; TNFSF-14) is a cytokine for inducing immune responses against tumors. A novel biochemical approach is used to decorate the surface of tumor cells with LIGHT. LIGHT decorated cells can be used to vaccinate and induce effective, sustained immunity against cells expressing neo or pathogen associated antigens. Variants of LIGHT are described that enhance binding to cellular receptors (e.g., LT beta receptor) and decrease regulation by inhibitors (e.g., Decoy Receptor 3) increasing ability to stimulate immunity.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: July 4, 2017
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Carl F Ware, Timothy C. Cheung, Theresia A. Banks
  • Patent number: 9637539
    Abstract: This invention features antibodies that specifically bind to a human Dragon family protein.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: May 2, 2017
    Assignee: The General Hospital Corporation
    Inventors: Clifford J. Woolf, Tarek A. Samad
  • Patent number: 9605042
    Abstract: Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: March 28, 2017
    Assignee: Regents of the University of Minnesota
    Inventors: Karen Hsiao Ashe, Xiaohui Zhao, Michael Anthony Walters, Derek John Hook, Morgan Clotaire Paul Le Naour
  • Patent number: 9598484
    Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 21, 2017
    Assignees: Biogen MA Inc., Biogen International Neuroscience GmbH
    Inventors: Paul H. Weinreb, Feng Chen, Ellen A. Garber, Jan Grimm, Fabio Montrasio
  • Patent number: 9598480
    Abstract: The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: March 21, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kang Ting, Chia Soo
  • Patent number: 9549971
    Abstract: The present invention provides methods of using EGFL8 antagonists to inhibit vascular development and to treat related disorders.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 24, 2017
    Assignee: GENENTECH, INC.
    Inventors: Weilan Ye, Han Lu
  • Patent number: 9518085
    Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: December 13, 2016
    Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECHNOLOGÍA
    Inventors: Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Penton Arias, Efrain Rodriguez Jimenez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lazaro Pardo Andreu, Luis Javier Gonzalez Lopez, Nancy Pavon Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio Lopez Saura
  • Patent number: 9498529
    Abstract: The present invention provides methods for treating or preventing influenza virus infection. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising a type II transmembrane serine protease (TTSP) inhibitor. The TTSP inhibitor preferably functions by inhibiting the proteolytic cleavage of influenza hemagglutinin (HA0) into the functional subunits HA1 and HA2. In certain embodiments, the TTSP inhibitor is an inhibitor of transmembrane protease serine S1 member 2 (TMPRSS2), such as an anti-TMPRSS2 antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: November 22, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Lisa A. Purcell Ngambo
  • Patent number: 9499847
    Abstract: A primer for the amplification of a DNA template comprising a protelomerase target sequence, particularly for production of closed linear DNA, which primer is capable of specifically binding to a palindromic sequence within a protelomerase target sequence and priming amplification in both directions.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: November 22, 2016
    Assignee: Touchlight IP Limited
    Inventors: Neil Porter, Lisa Caproni, Karen Oliver, Kinga Karbowniczek, Angus Knight
  • Patent number: 9447179
    Abstract: This invention concerns affinity tools for oligomeric forms of tau protein. It relates to the field of neurodegeneration, more particularly to the field of tau-related diseases and tauopathy. The invention provides novel tau antibodies and antibody fragments, nucleic acids encoding such antibodies and antibody fragments, cell lines producing such antibodies and antibody fragments, antibody compositions, and kits for the detection of aggregated tau and for the diagnosis of diseases involving aggregated tau. The invention further provides methods for the detection of aggregated tau, for the diagnosis of diseases involving aggregated tau, and for the identification of compositions interfering with the formation and/or stability of tau aggregates.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: September 20, 2016
    Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN, KU RESEARCH & DEVELOPMENT, FUJIREBIO EUROPE N.V.
    Inventors: Joris Winderickx, Eugeen Vanmechelen, Fred Van Leuven
  • Patent number: 9434991
    Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 6, 2016
    Assignee: Juneau Biosciences, LLC.
    Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
  • Patent number: 9403913
    Abstract: Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: August 2, 2016
    Assignee: OvaScience, Inc.
    Inventors: David T. Weaver, Bo Zhang
  • Patent number: 9394359
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: July 19, 2016
    Assignee: CHINA SYNTHETIC RUBBER CORPORATION
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Patent number: 9388452
    Abstract: The present invention relates to a method for determining the highest temperature that is suitable for performing accelerated protein stability studies, as well as to a method for modeling real-time protein stability from accelerated stability data generated at said temperature.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: July 12, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventor: Peter Matthiessen
  • Patent number: 9321837
    Abstract: The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: April 26, 2016
    Assignee: UCB PHARMA S.A.
    Inventors: Diane Marshall, Stevan Shaw
  • Patent number: 9290546
    Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: March 22, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Jian Yan
  • Patent number: 9290544
    Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 22, 2016
    Assignee: The Johns Hopkins University
    Inventors: Marc Alan Ostermeier, Gurkan Guntas
  • Patent number: 9285367
    Abstract: The developed reagent is three-color immunophenotyping reagent for measurement of CD4 positive lymphocytes in peripheral blood. The reagent contains 7-aminoactinomycin D (7-AAD) which intercalates into double stranded DNA and is easily excited at 488 nm. The fluorescence emission of 7-AAD has peak at 670 nm that can be detected with FL3 detector of flow cytometer. The 7-AAD, therefore, stains white blood cells and discriminates it from red blood cells. The reagent also contains fluorescein isothiocyanate (FITC) labeled CD4 monoclonal antibody and phycoerythrin (PE) labeled CD14 monoclonal antibody which are detected with FL1 and FL2 detectors of flow cytometer, respectively. The developed reagent can be used to measure number of CD4 positive lymphocytes in lymphocyte population and monitor monocyte contamination simultaneously. This reagent therefore provides more accuracy results of CD4 positive lymphocyte enumeration.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: March 15, 2016
    Assignees: National Science and Technology Development Agency, The Thailand Research Fund
    Inventor: Watchara Kasinrerk
  • Patent number: 9268862
    Abstract: A tracking system passively tracks and records searches conducted by actual search engine users. The recorded data for each search event preferably includes the search query submitted, the search engine used, the search result item (e.g., web page) selected, the position (e.g., page number) of this item, and the user's IP address. The collected data is aggregated and analyzed to generate data regarding the search queries used to locate and access particular destinations (e.g., web pages and sites). This data may be used for various purposes, such as (1) to generate reports showing, e.g., how users reach a particular destination from different search engines and geographic locations, (2) to select content to display on a destination page, such that the content is relevant to search queries commonly used to locate that page, and (3) to update the database of one search engine to reflect searches conducted on other search engines.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: February 23, 2016
    Assignee: Gere Dev. Applications, LLC
    Inventors: Richard Kazimierz Zwicky, Todd William Hooge, Matthew Dunn
  • Patent number: 9249210
    Abstract: Disclosed is an expression vector system for variants of coagulation Factor VIII (FVIII) and von Willebrand Factor (vWF). In detail, mutant vWF the size of which is significantly reduced by deleting exons but which has remarkably increased FVIII stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with FVIII are disclosed. Use of the mutant vWF with a reduced size enables effective expression of FVIII in a viral vector and significantly enhanced FVIII activity. Further, the viral vector may be effectively used to treat hemophilia through gene therapy.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: February 2, 2016
    Assignee: Korea University Industrial & Academic Collaborative Foundation
    Inventors: Sang Yun Choi, Sang Won Park
  • Patent number: 9228021
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 5, 2016
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Patent number: 9212227
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 15, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Patent number: 9193768
    Abstract: There are provided an angiopoietin-2 (Ang2) derived peptides, polypeptides, and peptide complexes, and a method for inhibition of binding between Ang2 and integrin and prevention and/or treatment of a disease caused by the activation of Ang2 or the binding between Ang2 and integrin using the peptide, polypeptides, and peptide complexes.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: November 24, 2015
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Sang Yeul Han, Chung Ho Kim, Kyung Eun Kim, Hyung-Chan Kim, Kwang-Hoon Lee, Hyo Seon Lee
  • Patent number: 9192650
    Abstract: The present invention provides compositions and methods to prevent apoptosis. In particular, provided herein are compositions and methods which prevent FAS-mediated photoreceptor apoptosis.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 24, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: David N. Zacks, Cagri Besirli
  • Patent number: 9166061
    Abstract: Provided is a transistor which includes an oxide semiconductor film and has stable electrical characteristics. In the transistor, over an oxide film which can release oxygen by being heated, a first oxide semiconductor film which can suppress oxygen release at least from the oxide film is formed. Over the first oxide semiconductor film, a second oxide semiconductor film is formed. With such a structure in which the oxide semiconductor films are stacked, the oxygen release from the oxide film can be suppressed at the time of the formation of the second oxide semiconductor film, and oxygen can be released from the oxide film in later-performed heat treatment. Thus, oxygen can pass through the first oxide semiconductor film to be favorably supplied to the second oxide semiconductor film. Oxygen supplied to the second oxide semiconductor film can suppress the generation of oxygen deficiency, resulting in stable electrical characteristics.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: October 20, 2015
    Assignee: Semiconcductor Energy Laboratory Co., Ltd.
    Inventor: Shunpei Yamazaki
  • Patent number: 9157085
    Abstract: An expression vector for expressing a target polypeptide in a prokaryotic cell is provided. The vector comprises a promoter operably linked to a polynucleotide encoding the target polypeptide operably linked to a eukaryotic secretion leader sequence, the eukaryotic secretion leader sequence encoding a signal peptide sequence selected from the group consisting of: a) MLKRSSWLATLGLLTVASVSTIVYA; b) MKKATFITCLLAVLLVSNPIWNA; c) MKVSAAALAVILIATALCAPASA; d) MKVSTAFLCLLLTVSAFSAQVLA; and e) MKCLLLALGLALACAAQA. Processes for expressing polypeptides and prokaryotic microorganisms comprising such vectors are also provided.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: October 13, 2015
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventors: Bhupendra Vallabh Kara, Christopher David John Lennon
  • Patent number: 9127321
    Abstract: The present invention provides methods and kits that may be used to detect and quantify the presence of Coccidioides species. The methods include quantification PCR assays, and the kits and compositions include oligonucleotides used as primers and probes.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: September 8, 2015
    Assignees: The Translational Genomics Research Institute, The Arizona Board of Regents on Behalf of Northern Arizona University
    Inventors: David Engelthaler, Elizabeth Driebe, Paul Keim
  • Patent number: 9121853
    Abstract: Methods of evaluating patients by assessing expression of B7-H4 in the vasculature are described.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: September 1, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Eugene D. Kwon, John Cheville
  • Patent number: 9114116
    Abstract: The present invention relates to compositions and methods for neuroprotection. In particular, provided herein are compositions (e.g., hepatocyte secretory factors) for alleviating and/or protecting against neuronal damage (e.g., resulting from stroke), and methods of use thereof.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: August 25, 2015
    Assignee: NORTHWESTERN UNIVERSITY
    Inventor: Shu Q. Liu
  • Patent number: 9101585
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: August 11, 2015
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 9090694
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 28, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu